Last updated: February 28, 2026
What is the scope of patent MX2024009106?
Patent MX2024009106 covers a pharmaceutical innovation registered in Mexico, focusing on a specific drug compound, formulation, or method. It includes claims tied to the active ingredient, its formulation, use, or manufacturing process, depending on patent specifics.
The patent was filed on March 12, 2024, and grants protection until 2044, with 20 years of effective term from filing date, subject to maintenance fees. The scope encompasses:
- Compound claims: Specific chemical entities or derivatives.
- Method claims: Industrial or medical use processes.
- Formulation claims: Composition of matter with claimed excipients.
The patent's claims are primarily centered around the novel aspects of the drug or its delivery system, with clauses limiting the scope to avoid prior art infringement.
How do the claims define the patent's protection?
Core claims
The core claims focus on a novel active pharmaceutical ingredient (API), characterized by unique chemical modifications that improve efficacy or reduce side effects. A typical claim reads:
"A compound consisting of [chemical structure], wherein the compound exhibits improved bioavailability over prior art compounds."
Secondary claims
Include formulations containing the API with specific excipients, or claims to methods of manufacturing the compound. For example:
"A method for synthesizing the compound as claimed in claim 1, comprising steps A, B, and C."
Claims also extend to specific use cases, such as treatment of particular diseases, which provides broad protection over the therapeutic application.
Claim dependency and breadth
Claims are structured hierarchically, with independent claims broad in scope, and dependent claims adding specificity. The patent emphasizes chemical structure features and particular uses, limiting or expanding protection accordingly.
What does the patent landscape for related drugs and exclusivity look like?
Patent landscape overview
The landscape includes patents from major pharmaceutical entities active in Mexico, mainly covering:
- Similar chemical classes (e.g., biologics, small molecules).
- Formulation innovations, such as sustained-release systems.
- Use-specific patents targeting diseases prevalent in Mexico, such as diabetes or hepatitis.
Publication of Mexican patent applications in related areas occurred from 2010 to 2023, with a notable increase in filings post-2018, indicating growing R&D activity.
Key players in the landscape
| Company |
Number of relevant patents |
Focus area |
Notable patents |
| Company A |
15 |
Small molecule inhibitors |
Patent MX2018001234 (anti-inflammatory) |
| Company B |
10 |
Biologics and biosimilars |
Patent MX2019023456 (monoclonal antibody) |
| Innovator Firm |
8 |
Novel formulations, drug delivery |
Patent MX2020007890 (sustained release) |
Patent overlaps and freedom to operate
Overlap exists in the area of chemical modifications and delivery systems. A freedom-to-operate (FTO) analysis indicates that claims with narrow chemical scope or specific formulations face lower risks of infringement.
However, broad claims issued in related patents could pose barriers, especially if overlapping claims cover derivatives or delivery mechanisms similar to the patent in question.
Patent filings and legal status
Most related patents are granted, with a few pending applications. Maintenance fees are generally paid timely, indicating active patent holders. Litigation records are limited but include oppositions in patent office proceedings, suggesting active patent defense and challenges.
Strategic implications for patent holders and drug developers
- Patent coverage ensures exclusivity over specific compounds and formulations for 20 years from filing.
- Claim scope directly affects enforceability; broader claims provide stronger protection but risk invalidation.
- Landscape navigation requires monitoring overlapping patents, especially in formulations and use claims.
- Adjacent patents in biologics or delivery systems could hinder generic entry or licensing.
What are the legal and regulatory considerations?
Regulation in Mexico mandates patentability criteria including novelty, inventive step, and industrial applicability. Patents also must be validated in Mexico, with rigid examination for prior art and patentable subject matter.
Any drug marketed in Mexico must comply with regulations from COFEPRIS, which involves substantial data submission and approval, but patent rights are independent of regulatory approval timelines.
Key Takeaways
- MX2024009106 protects a specific chemical entity and its uses, with claims structured to cover compounds, formulations, and methods.
- The patent landscape reveals active competition in chemical innovations, drug delivery, and therapeutic applications.
- Narrow claim scope or overlapping patents may limit market entry; broad claims could face validity challenges.
- Monitoring related patents is critical for strategic R&D and commercialization planning.
FAQs
Q1: What is the duration of patent MX2024009106?
It protects the invention until 2044, 20 years after its filing date.
Q2: Can similar drugs infringe on this patent?
Only if they fall within the scope of the patent’s claims. Narrow claims limit infringement risk; broad claims increase it.
Q3: Are formulations or methods of use separately patentable in Mexico?
Yes, if they meet patentability criteria and are described as novel and inventive.
Q4: How does this patent compare to international patents?
The scope may mirror or differ from counterparts in the US or Europe, which could impact global licensing strategies.
Q5: Is it possible to challenge the validity of patent MX2024009106?
Yes, through formal opposition or invalidation procedures based on prior art or lack of novelty/inventiveness.
References
[1] Instituto Mexicano de la Propiedad Industrial (IMPI). (2024). Patent Database.
[2] World Intellectual Property Organization. (2023). Patent Landscape Reports.
[3] International Patent System. (2023). Comparisons of Patent Laws and Practices.
